Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian share markets soar higher
Fri, 22 Nov 01:30 pm

Indian share markets continued to climb higher in the post-noon trading session. Majority of the sectoral indices are trading in the green with consumer durable, oil & gas and capital goods stocks being the biggest gainers. Auto, realty and metal are the only stocks trading in the red.

BSE-Sensex is up 139 points and NSE-Nifty is trading 35 points up. BSE Mid Cap is trading up 0.5% and BSE Small Cap is trading up 0.6%. The rupee is trading at 62.5 to the US dollar.

Majority of the large software stocks are trading in the green with Info Edge and NIIT being the biggest gainers. However, HCL Tech and HCL Infosys are among the few stocks trading in the red. As per a leading financial daily, IT companies are making India the testing hub for their healthcare solution products that they intend to sell to healthcare providers in the US. Indian IT companies such as Wipro, TCS, and HCL Technologies are working with large hospital chains to fine-tune their healthcare solution products. Wipro is working with Apollo hospitals to pilot a foetus monitoring device. This device enables doctors to monitor vital parameters of the baby remotely thereby cutting down frequent clinic trips of women in advanced stages of pregnancy. TCS in association with Apollo Hospitals is digitizing the records of over two million patients for electronic management. HCL Tech is working with a pharma company to aid middle-aged women in India to mange asthama through mobile health solutions.

Most of the Indian pharma stocks are trading in the green with JB chemicals and Cadila healthcare being the major gainers. As per the financial daily, Biocon Ltd has got approval for Herceptin generic from the Indian drug regulator; Drug controller General of India(DCGI). Reportedly, the company has still not mentioned as to when it will launch the drug. This will be second biosimilar launch by the company in the Indian market. Herceptin is Roche's drug and some time back the company had withdrawn its patent on Herceptin in India. Roche had expectedly dropped claims for a patent on drug by not applying for a renewal of its existing patent in India. Herceptin is indicated for breast cancer, generically also known as Trastuzumab. The said drug being a biologic is not easy to develop and hence has high entry barriers. This approval is certainly positive development for Biocon. Biocon is currently trading up by 1.95%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets soar higher". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.